How effective is Militizumab, a specific drug for treating intestinal ulcers?

In recent years, with the deepening understanding of the mechanisms of chronic inflammatory bowel disease (IBD), more and more targeted treatments have been developed to improve patients' clinical symptoms and quality of life. Mirikizumab(Mirikizumab)It is in this context that a new therapeutic drug has gained widespread attention. In European and American medical research and clinical practice, militizumab has been considered an important breakthrough in the treatment of moderate to severe ulcerative colitis.

Intestinal ulcer is not a strictly defined independent disease. It is usually a manifestation of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. Therefore, discussing the effect of milizumab is also discussing its efficacy in this type of pathological state.

Milizumab is a humanized IgG4 monoclonal antibody that mainly targets the p19 subunit of interleukin-23 (IL-23) and blocks its binding to the IL-23 receptor. IL-23 is a pro-inflammatory cytokine that plays a central role in the pathogenesis of chronic intestinal inflammation, especially in the differentiation and maintenance of T-helper 17 (Th17) cells. By interfering with the IL-23 signaling pathway, militizumab can effectively reduce the immune activity of the intestinal mucosa and reduce the infiltration of inflammatory cells, thereby inhibiting the formation of intestinal ulcers and promoting mucosal repair.

Compared with traditional treatments such as glucocorticoids, 5-aminosalicylic acid preparations and immunosuppressants, militizumab is more precise in its treatment mechanism and has relatively fewer side effects. It is especially suitable for patients who have poor response to existing treatments or are troubled by side effects. According to the clinical review opinions of European and American drug regulatory agencies, militizumab has shown dual advantages in inducing remission and maintaining remission. Some patients can observe significant improvement in symptoms in the early stages of use, such as reduction in diarrhea, relief of bloody stools, and relief of abdominal pain. In addition, militizumab also has better performance in promoting mucosal healing, which is considered a key prognostic indicator in the treatment of chronic enteritis.

Reference materials:https://omvoh.lilly.com/